Valuation: Middle East Pharmaceutical Industries Company

Market Cap 2.1B 560M 500M 458M 417M 782M 52.97B 797M 5.48B 2.21B 27.96B 2.06B 88.31B P/E 2024
30.5x
P/E 2025 22.9x
Enterprise Value 2.13B 567M 507M 465M 423M 793M 53.72B 809M 5.55B 2.24B 28.35B 2.08B 89.55B EV / Sales 2024
6.29x
EV / Sales 2025 4.89x
Free-Float
46.88%
Yield 2024
1.64%
Yield 2025 2.18%
Oct. 11 Avalon Pharma Signs 10-year Licensing Agreement With OneSource Specialty Pharma MT
Oct. 11 Middle East Pharmaceutical Industries Co. And OneSource Specialty Pharma Limited Announce Signing Of A License Agreement For Tirzepatide, A Generic Of Mounjaro® KwikPen®, In The Kingdom Of Saudi Arabia And The MENA Region CI
Oct. 07 Avalon Pharma, Aurisco to Cooperate on Oligonucleotide Manufacturing in Saudi Arabia MT
Oct. 07 Middle East Pharmaceutical Industries Co. and Aurisco Pharma Sign Memorandum of Understanding for Strategic Cooperation on Oligonucleotide and Other Complex Pharmaceutical Products CI
Sep. 17 Avalon Pharma Renews SAR104 Million Bank Facility Deal with Banque Saudi Fransi MT
Aug. 27 Avalon Pharma Reiterated at Overweight as Aljazira Capital Notes 'Solid' Q2 Growth MT
Aug. 20 Avalon Pharma Renews SAR50 Million Credit Facility MT
Aug. 18 Bio-Thera Solutions and Avalon Pharma are deepening their collaboration on BAT2406 in Saudi Arabia and other Middle Eastern and North African markets CI
Aug. 18 Avalon Pharma Wins 15-year Exclusive Biosimilar License Deal in Saudi Arabia MT
Aug. 10 Avalon Pharma Declares H1 Dividend MT
Aug. 10 Middle East Pharmaceutical Industries Company Announces Cash Dividends for the First Half of 2026, Payable on September 15, 2026 CI
Aug. 09 Middle East Pharmaceutical Industries Company Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
Aug. 06 Avalon Pharma Posts Growth in H1 Net Profit, Revenue MT
1 day+0.33%
1 week+1.09%
Current month-1.63%
1 month-3.99%
3 months+3.26%
6 months+1.01%
Current year-5.26%
1 week 59.2
Extreme 59.2
61.8
1 month 55.6
Extreme 55.6
64.7
Current year 53.89
Extreme 53.885712
68.51
1 year 53.89
Extreme 53.885712
75.2
3 years 51.54
Extreme 51.542856
112.91
5 years 51.54
Extreme 51.542856
112.91
10 years 51.54
Extreme 51.542856
112.91
Manager TitleAgeSince
Chief Executive Officer 45 2018-09-04
Director of Finance/CFO - 2024-03-10
Chief Tech/Sci/R&D Officer 51 2022-12-31
Director TitleAgeSince
Chairman 54 2022-04-09
Director/Board Member 45 2023-09-12
Director/Board Member 45 2022-04-09
Change 5-day change 1-year change 3-year change Capi.($)
+0.33%+1.09%-20.19% - 560M
-0.46%+10.31%+63.52%+143.15% 1,257B
-0.97%+1.60%+43.25%+80.09% 651B
-2.05%+0.73%+32.47%+101.62% 510B
-1.54%+0.18%+53.42%+66.79% 388B
-0.78%+5.51%+72.55%+44.25% 366B
-1.69%+3.17%+32.49%+55.35% 303B
-0.72%+7.83%+11.15%+33.76% 288B
-0.12%+4.68%+55.97%+74.59% 252B
-0.21%+7.34%+42.19%+109.69% 211B
Average -0.75%+4.37%+38.68%+78.81% 422.72B
Weighted average by Cap. -0.73%+5.30%+49.18%+93.33%

Financials

2024 2025
Net sales 394M 105M 93.73M 86.01M 78.24M 147M 9.94B 150M 1.03B 414M 5.25B 386M 16.57B 460M 123M 110M 101M 91.44M 171M 11.62B 175M 1.2B 484M 6.13B 451M 19.36B
Net income 79.85M 21.28M 18.99M 17.43M 15.86M 29.73M 2.01B 30.32M 208M 83.92M 1.06B 78.15M 3.36B 97.01M 25.85M 23.08M 21.18M 19.26M 36.12M 2.45B 36.84M 253M 102M 1.29B 94.94M 4.08B
Net Debt 42.83M 11.41M 10.19M 9.35M 8.51M 15.95M 1.08B 16.26M 112M 45.02M 570M 41.92M 1.8B 29.47M 7.85M 7.01M 6.43M 5.85M 10.97M 743M 11.19M 76.85M 30.98M 392M 28.84M 1.24B
Projected Income Statement - Annual - Middle East Pharmaceutical Industries Company
Logo Middle East Pharmaceutical Industries Company
Middle East Pharmaceutical Industries Company SJSC is a Saudi Arabia-based pharmaceutical company. The Company develops, manufactures, markets, and distributes a wide range of generic medicines and pharmaceuticals. The Company’s activity is the manufacture of disinfectants and sterilizers for medical devices and products, the manufacture of disinfectants and sterilizers for non-medical use, the manufacture of cosmetics, and the manufacture of pharmaceutical preparations for human use.
Employees
731
Date Price Change Volume
26-11-03 SAR 60.15 +0.25% 3,809
26-11-02 SAR 60.00 +1.35% 150,650
26-11-01 SAR 59.20 -3.27% 56,647
26-10-29 SAR 61.20 +0.41% 45,471
26-10-28 SAR 60.95 +2.35% 73,733
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Middle East Pharmaceutical Industries Company
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
60.00SAR
Average target price
146.40SAR
Spread / Average Target
+144.00%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Middle East Pharmaceutical Industries Company
  1. Stock Market
  2. Stocks
  3. 4016 Stock